Connecting the Lab to Everyday Life: The Relevance of Executive Dysfunction to Participation and Quality of Life in Parkinson's Disease (PD) Without Dementia - Full Text View

Connecting the Lab to Everyday Life: The Relevance of Executive Dysfunction to Participation and Quality of Life in Parkinson's Disease (PD) Without Dementia (Lab2Life)

This study is currently recruiting participants.

Verified November 2011 by Washington University School of Medicine

First Received on June 8, 2009. Last Updated on November 8, 2011 History of Changes

Sponsor:	Washington University School of Medicine
Information provided by (Responsible Party):	Erin Foster, Washington University School of Medicine
ClinicalTrials.gov Identifier:	NCT00917280

Purpose

The overall purpose of this research is to learn how Parkinson's disease affects thinking and memory in everyday life. Participation will involve thinking tests, questionnaires and interviews about thinking and activities in everyday life.

Condition
Parkinson's Disease

Study Type:	Observational
Study Design:	Observational Model: Case Control Time Perspective: Cross-Sectional
Official Title:	Connecting the Lab to Everyday Life: The Relevance of Executive Dysfunction to Participation and Quality of Life in PD Without Dementia

Resource links provided by NLM:

Genetics Home Reference related topics: familial paroxysmal nonkinesigenic dyskinesia Parkinson disease Perry syndrome

MedlinePlus related topics: Dementia Parkinson's Disease

U.S. FDA Resources

Further study details as provided by Washington University School of Medicine:

Estimated Enrollment:	180
Study Start Date:	December 2008

Groups/Cohorts
Parkinson's Disease Parkinson Disease participants without dementia
Control Non-PD participants, matched for age, education and gender.

Detailed Description:

Eligibility

Ages Eligible for Study:	40 Years to 70 Years
Genders Eligible for Study:	Both
Accepts Healthy Volunteers:	Yes
Sampling Method:	Non-Probability Sample

Study Population

Controls:

Recruited from community, VFH.

Criteria

Inclusion Criteria PD participants:

WUSM Movement Disorders Clinic patients
males or females between 40 and 70
meet criteria for idiopathic typical PD
classified at Hoehn & Yahr12 stage I, II, or III
are currently treated with levodopa/carbidopa

Inclusion Criteria Control:

The groups will be matched for age, education and gender
No Parkinson Disease

Exclusion Criteria PD participants and Control:

suspected dementia
treatment with certain dopaminergic, anticholinergic or benzodiazepine medications
other neurological problems
brain surgery
history or current psychotic disorder
any condition which would interfere with testing
control only: a biological family history of PD and being a caregiver or spouse of someone who has PD

Contacts and Locations

Please refer to this study by its ClinicalTrials.gov identifier: NCT00917280

Contacts

Contact: Tasha Doty, MA	314-362-7160	dotyt@npg.wustl.edu
Contact: Erin Foster, OTD, OTR/L	314-286-1638	erfoster@wustl.edu

Locations

United States, Missouri
Washington University School of Medicine	Recruiting
St. Louis, Missouri, United States, 63110
Contact: Erin R Foster, PhD. 314-286-1638 erfoster@WUSTL.edu
Principal Investigator: Erin Foster, OTD

Sponsors and Collaborators

Washington University School of Medicine

Investigators

Principal Investigator:

Erin Foster

Washington University School of Medicine

More Information

No publications provided

Responsible Party:	Erin Foster, Assistant Professor of Occupational Therapy, Neurology and Psychiatry, Washington University School of Medicine
ClinicalTrials.gov Identifier:	NCT00917280 History of Changes
Other Study ID Numbers:	#E07-117
Study First Received:	June 8, 2009
Last Updated:	November 8, 2011
Health Authority:	United States: Institutional Review Board

Keywords provided by Washington University School of Medicine:

Parkinson's Disease

Additional relevant MeSH terms:

Dementia
Parkinson Disease
Brain Diseases
Central Nervous System Diseases
Nervous System Diseases
Delirium, Dementia, Amnestic, Cognitive Disorders

Mental Disorders
Parkinsonian Disorders
Basal Ganglia Diseases
Movement Disorders
Neurodegenerative Diseases

ClinicalTrials.gov processed this record on February 09, 2012